Why Pfizer-Allergan inversion criticism is misplaced

December 01, 2015

The record-breaking merger has attracted fierce criticism, but the focus should be on US authorities’ deceptive use of guidance

Unlock this content.

The content you are trying to view is exclusive to our subscribers.

To unlock this content:

Take a Free Trial or Login

Topics

Corporate Deals M&A IFLR Magazine December/January 2016 Ireland United States

Tom Young